November 9, 2021 | Customer Poster
Nanoparticle-Based Method Identifies 2,200 Proteins in a Cardiovascular Disease Study Covering Known Biomarkers Among Other Differentially Expressed Proteins
American Society of Mass Spectrometry – Michael Burgess, et al.
This collaboration with the Broad Institute presented at the American Society for Mass Spectrometry describes a Proteograph™ application for cardiovascular biomarker research using deep plasma proteomics. Over 2000 proteins were detected in each individual patient sample with a total of over 4000 across 16 samples.
Overview
- Plasma is an ideal sample for clinical proteomics but analysis is confounded by the intrinsic high dynamic range of plasma proteins making confident and reproducible measurement of low abundance proteins difficult.
- In a previous cardiovascular disease study, our proteomics workflow involving abundant protein depletion, iTRAQ-labeling, off-line basic reversed-phase fractionation and analysis of 30 fractions by LC-MS/MS quantified over 3500 proteins including the measurement of clinical markers such as troponins I and T, but at the cost of extended labor, cost and low throughput 2. Specifically, to process 16 patient samples required 7-10 days of lab work followed by 120 LC-MS/MS runs.
- Here we compare this strategy with the newly developed Proteograph Product Suite (Seer) which simplifies sample processing prior to MS analysis by using nanoparticles in a robotic platform with much higher throughput.
Discover Seer Technology Access Programs & Services
Easily explore the protein universe with Seer. Our service providers and in-house Seer Technology Access Center (STAC) empower your research, accelerating results and deciphering the proteome at unprecedented depth and scale. Answer biology’s most challenging questions — faster.